What is the role of Ragwitek in the treatment of allergic rhinitis (hay fever)?

Updated: Dec 26, 2018
  • Author: Javed Sheikh, MD; Chief Editor: Michael A Kaliner, MD  more...
  • Print
Answer

A third SL immunotherapy for ragweed (Ragwitek) was also approved in April 2014 for adults aged 18 years or older. Effectiveness studies included about 760 patients. Phase 3 clinical trials showed reduced rhinoconjunctivitis symptoms over the entire season by 27-43% compared with placebo. Ragwitek is approved for adults aged 18 years or older. [71, 72]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!